---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-000158"
form_type: "8-K"
ticker: "USNA"
cik: "0000896264"
company_name: "USANA HEALTH SCIENCES INC"
filed_at: "2022-02-08T23:59:59+00:00"
generated_at: "2026-06-27T10:25:37.529111+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# USANA Q4 net sales $267M (-14% YoY), EPS $1.03; FY22 guidance $5.25-$6.00 EPS

## Summary
- Q4 net sales $267.3M (-14% YoY), diluted EPS $1.03 (-45% YoY); active customers 560K (-7% YoY).
- FY2021 net sales $1.186B (+5% YoY); diluted EPS $5.73 (-2% YoY); FX benefit $53.6M.
- FY2022 guidance: net sales $1.125-$1.225B; diluted EPS $5.25-$6.00; expects net sales acceleration.
- Q4 regional: Asia Pacific -15%, Americas/Europe -11%; COVID disruptions hurt key markets; Southeast Asia Pacific -26%.
- Ended Q4 with $240M cash, no debt; repurchased 296K shares for $28.9M; $108M buyback remaining.

## SEC filing metadata
- accession: 0001157523-22-000158
- form_type: 8-K
- ticker: USNA
- cik: 0000896264
- company_name: USANA HEALTH SCIENCES INC
- filed_at: 2022-02-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/896264/000115752322000158/0001157523-22-000158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/896264/000115752322000158/a52576017.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-000158
- JSON: https://secwatch.observer/filing/0001157523-22-000158.json
- Plain text: https://secwatch.observer/filing/0001157523-22-000158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.